当前位置: 首页 > 期刊 > 《世界中医药》 > 202012
编号:13472247
芪归方有效组分治疗特发性肺纤维化的实验研究(5)
http://www.100md.com 2020年6月15日 《世界中医药》 202012
     [9]Na M,Hong X,Fuyu J,et al.Proteomic profile of TGF-β1 treated lung fibroblasts identifies novel markers of activated fibroblasts in the silia exposed rat lung[J].Exp Cell Res,2019,375(2):1-9.

    [10] Budi EH,Xu J,Derynck R.Regulation of TGF-β Receptors[J].Methods Mol Biol,2016,1344:1-33.

    [11]Xu F,Liu C,Zhou D,et al.TGF/SMAD pathways and its regulation in hepatic fibrosis[J].J Histochem Cytochem,2016,64(3):157-167.

    [12]Zeglinski MR,Hnatowich M,Jassal DS,et al.SnoN as a novel negative regulator of TGF-β/Smad signaling:a target for tailoring organ fibrosis[J].Am J Physiol Heart Circ Physiol,2015,308(2):H75-82.

    [13]Liu L,Shi M,Wang Y,et al.SnoN upregulation ameliorates renal fibrosis in diabetic nephropathy[J].PLoS One,2017,12(3):e0174471.

    [14]曹述任,楊俊侠,张敏.MG132抑制TGF-β1诱导的人肺成纤维细胞活化[J].基础医学与临床,2016,36(2):156-160.

    [15]Wang J,Li HY,Wang HS,et al.MicroRNA-485 Modulates the TGF-β/Smads Signaling Pathway in Chronic Asthmatic Mice by Targeting Smurf2[J].Cell Physiol Biochem,2018,51(2):692-710.

    (2020-04-25收稿 责任编辑:王杨), 百拇医药(彭艳芳 张莹雯 张亚兵)
上一页1 2 3 4 5